ARTICLE | Company News
Corvas, Schering-Plough deal
March 8, 1999 8:00 AM UTC
CVAS reacquired the exclusive development and commercialization rights to recombinant Nematode Anticoagulant Protein 5 (rNAP5) covered in the companies' 1994 agreement. CVAS said that because rNAP5 is...